Peptide therapeutics have emerged as a major pharmaceutical class, with over 80 approved peptide drugs and hundreds in clinical development. This guide covers the complete pipeline from target identification to market approval.
| Phase | Duration | Success Rate | Key Activities |
|---|
| Discovery | 1–3 years | ~50% to IND | Target ID, hit identification, lead optimization |
| Preclinical | 2–4 years | ~60% to Phase 1 | Safety, pharmacology, toxicology, CMC |
| Phase 1 | 1–2 years | ~70% to Phase 2 | Safety, PK, dose finding (20–100 subjects) |
| Phase 2 | 2–3 years | ~35% to Phase 3 | Efficacy, dose response (100–500 subjects) |
| Phase 3 | 3–4 years | ~60% to NDA | Confirmatory efficacy, safety (1,000–5,000 subjects) |
| NDA/BLA | 1–2 years | ~85% approval | Regulatory review, approval |
| Total | 10–15 years | ~5–10% overall | — |
| Criterion | Requirement | Assessment |
|---|
| Biological relevance | Validated disease pathway | Genetic, literature evidence |
| Druggability | Peptide-accessible binding site | Structural biology |
| Safety window | Therapeutic index >10 | Preclinical modeling |
| Market potential | Unmet medical need | Commercial analysis |
| Method | Approach | Timeline |
|---|
| Genetic knockout | CRISPR, siRNA | 6–12 months |
| Antibody blockade | Neutralizing antibodies | 3–6 months |
| Peptide mimetics | Synthetic peptide screening | 3–6 months |
| Computational modeling | In silico target analysis | 1–3 months |
| Approach | Method | Throughput |
|---|
| Random peptide libraries | Phage display, mRNA display | 10⁹–10¹² variants |
| Rational design | Structure-based, homology modeling | 10–100 candidates |
| Natural product screening | Extract screening | 10³–10⁵ samples |
| AI/ML prediction | Deep learning models | In silico |
- Binding affinity: SPR, ITC, fluorescence polarization
- Functional activity: Cell-based assays
- Selectivity: Counter-screening against related targets
- Physicochemical properties: Solubility, stability, aggregation
| Parameter | Target | Modification Strategy |
|---|
| Potency | EC₅₀ <10 nM | Sequence optimization, cyclization |
| Selectivity | >100-fold over off-targets | Structure-activity relationships |
| Half-life | >4 hours (therapeutic window) | PEGylation, albumin binding, D-amino acids |
| Bioavailability | >20% (oral) or >80% (SC) | Permeation enhancers, formulation |
| Stability | >90% at 24 hours (serum) | D-amino acids, N-methylation, cyclization |
| Solubility | >1 mg/mL | Charge optimization, formulation |
| Modification | Purpose | Effect on Properties |
|---|
| N-terminal acetylation | Protease resistance | ↑ Stability |
| C-terminal amidation | Protease resistance, charge | ↑ Stability, altered charge |
| D-amino acid substitution | Protease resistance | ↑↑ Stability, ↓ bioactivity |
| PEGylation | Half-life extension | ↑↑ Half-life, ↓ potency |
| Albumin binding | Half-life extension | ↑↑ Half-life |
| Cyclization | Stability, conformation | ↑ Stability, ↑ potency |
| N-methylation | Permeability, stability | ↑ Oral bioavailability |
| Disulfide bridge | Conformational constraint | ↑ Potency, ↑ stability |
| Study | Duration | Animals | Endpoints |
|---|
| Single-dose toxicity | 1–2 weeks | 2 species | MTD, NOAEL |
| Repeat-dose toxicity | 28–90 days | 2 species | Organ toxicity, histopathology |
| Safety pharmacology | 2–4 weeks | 1–2 species | CV, respiratory, CNS |
| Genotoxicity | 2–4 weeks | In vitro + in vivo | Mutagenicity |
| Reproductive toxicity | 3–6 months | 2 species | Fertility, teratogenicity |
| Carcinogenicity | 24–36 months | 2 species (if indicated) | Tumor incidence |
| Component | Requirements |
|---|
| Drug substance | Synthesis, purification, characterization |
| Drug product | Formulation, stability, container closure |
| Analytical methods | Validation, specifications |
| Manufacturing process | Scale-up, GMP compliance |
| Quality control | Release testing, stability program |
Objective: Safety, tolerability, pharmacokinetics
| Design Element | Typical Approach |
|---|
| Subjects | 20–100 healthy volunteers or patients |
| Duration | 1–2 years |
| Endpoints | Safety, PK, PD, MTD |
| Design | Single ascending dose, multiple ascending dose |
| Budget | $5–15 million |
Objective: Efficacy, dose response, side effect profile
| Design Element | Typical Approach |
|---|
| Subjects | 100–500 patients |
| Duration | 2–3 years |
| Endpoints | Efficacy, safety, dose-response |
| Design | Randomized, controlled, blinded |
| Budget | $20–50 million |
Objective: Confirmatory efficacy, safety, benefit-risk
| Design Element | Typical Approach |
|---|
| Subjects | 1,000–5,000 patients |
| Duration | 3–4 years |
| Endpoints | Clinical efficacy, safety, QoL |
| Design | Multi-center, randomized, double-blind |
| Budget | $100–300 million |
| Section | Content |
|---|
| Chemistry | Drug substance, drug product, manufacturing |
| Pharmacology | Mechanism of action, pharmacology |
| Clinical | Efficacy, safety, PK/PD |
| Statistical | Analysis plans, results |
| Labeling | Proposed prescribing information |
| Pathway | Purpose | Benefit |
|---|
| Fast Track | Serious conditions, unmet need | Rolling review, frequent meetings |
| Breakthrough | Substantial improvement over existing | Enhanced guidance, rolling review |
| Priority Review | Significant improvement | 6-month review (vs 10–12) |
| Accelerated Approval | Surrogate endpoint | Earlier approval, confirmatory trials |
| Orphan Drug | Rare diseases | 7-year exclusivity, tax credits |
| Challenge | Solution |
|---|
| Scale-up | Solid-phase or hybrid synthesis |
| Purity | Advanced purification (HPLC, IEX) |
| Cost | Generic manufacturing, biosimilars |
| Quality | GMP compliance, analytical validation |
| Challenge | Solution |
|---|
| Oral delivery | Permeation enhancers, nanoparticle encapsulation |
| Stability | Lyophilization, PEGylation |
| Immunogenicity | Humanization, modification |
| Half-life | Albumin binding, depot formulations |
| Category | Examples | Annual Revenue (est.) |
|---|
| Diabetes/Obesity | Semaglutide, Liraglutide, Tirzepatide | $50B+ |
| Oncology | Octreotide, Leuprolide | $5B+ |
| Cardiovascular | Eptifibatide, Bivalirudin | $2B+ |
| Bone | Teriparatide, Abaloparatide | $1B+ |
| Reproductive | GnRH agonists, Oxytocin | $2B+ |
| Anti-infective | Daptomycin, Polymyxin | $1B+ |
| Phase | Agents | Indication |
|---|
| Phase 3 | Orforglipron | Oral obesity |
| Phase 3 | Retatrutide | Obesity (triple agonist) |
| Phase 2 | Survodutide | Obesity, NASH |
| Phase 2 | Amycretin | Oral obesity |
| Phase 1 | Various oral GLP-1 | Oral delivery |
- FDA. “Peptide Drug Products: Technical Considerations.” FDA Guidance 2023.
- Lau JL, Dunn MK. “Therapeutic peptides: Historical perspectives, current development trends, and future directions.” Bioorg Med Chem 2018;26:2700-2707.
